Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Izotropic Corp (CSE: IZO )

0.2600 +0.0650 (+33.33%)
Official Closing Price Updated: 3:54 PM EST, Jan 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 204,000
Open 0.1950
Bid (Size) 0.2600 (4,500)
Ask (Size) 0.2700 (5,000)
Prev. Close 0.1950
Today's Range 0.1950 - 0.2600
52wk Range 0.0350 - 0.2600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening
-A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView... 
Via Newsfile
Exposures Product Safety
Izotropic Provides Regulatory and Operational Updates
VANCOUVER, BC – TheNewswire - January 8, 2024 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE:IZO) (OTC:IZOZF) (FSE:1R3), a medical device company commercializing IzoView, a CT (computed... 
Via TheNewswire.com
Exposures Product Safety

Performance

YTD
+160.00%
+160.00%
1 Month
+550.00%
+550.00%
3 Month
+205.88%
+205.88%
6 Month
+225.00%
+225.00%
1 Year
+52.94%
+52.94%

More News

Read More
Izotropic Announces AGM Results
Via TheNewswire.com
Izotropic Completes Pre-Submission Meeting With U.S. FDA
Via TheNewswire.com
Exposures Product Safety
Izotropic Confirms FDA Pre-Submission Meeting Date
Via TheNewswire.com
Exposures Product Safety
Izotropic Closes Non-Brokered Private Placement
Via TheNewswire.com
Izotropic Corporation Announces Non-Brokered Private Placement
Via TheNewswire.com
Izotropic Files Class II Pre-Submission with FDA & Releases Details on Predicate Devices
Via TheNewswire.com
Exposures Product Safety
Izotropic Engages Market Awareness Consultant
Via TheNewswire.com
Izotropic Modifies Market Approval Pathway & Strategy
Via TheNewswire.com
Exposures Product Safety
Izotropic Completes QSUB Meeting With FDA Regarding Clinical Study Acceleration
Via TheNewswire.com
Exposures Product Safety
Izotropic Provides Business Update
Via TheNewswire.com
Izotropic to Extend Period for Unsecured Loans
Via TheNewswire.com
Izotropic's Izoview Breast CT Device to be Featured on Advancements TV Show in USA
Via TheNewswire.com
Izotropic Creates Compensation Committee and Adopts Charter
Via TheNewswire.com
Izotropic Releases First Video of IzoView
Via Newsfile
Izotropic Releases First Video of Izoview
Via TheNewswire.com
Izotropic Reports Board Meeting Results
Via TheNewswire.com
Izotropic Delays Announcements to 2023, Holds Board Meeting
Via TheNewswire.com
Izotropic Announces 2022 AGM Results and Clarifies Restating of Financial Statements
Via TheNewswire.com
Izotropic Completes Izoview Development and Assembly, Prepares for Final Testing
Via TheNewswire.com
Alexander Tokman Joins Izotropic Board Of Directors
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence
IZOTROPIC CORPORATION Announces Closing of Non-Brokered Private Placement
Via TheNewswire.com
Izotropic Grants Stock Options
Via TheNewswire.com
Izotropic Appoints Medical Device R&D Expert as Executive VP of Product Engineering
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.